SciSparc (SPRCY) Stock Price, News & Analysis

Company Overview

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. SciSparc Ltd. has an agreement with Procaps to develop and commercially manufacture SCI-110, as well as CannAmide, a palmitoylethanolamide compound in softgel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to perform a pre-clinical study for the evaluation of SCI-210 drug development program for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv, Israel.

Key Stats

• Today's Range: $3.99 to $4.90
• 50-Day Range: $4.00 to $4.00
• 52-Week Range: $2.75 to $12.25
• Volume: 12,500 shs
• Average Volume: 10,035 shs
• Market Capitalization: $4.15 million
• P/E Ratio: 0.27
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:SPRCY
• CUSIP: N/A
• CIK: 1611746
• Web: therapixbio.com
• Phone: 972-3610-3100
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: 0.27
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.05
• Quick Ratio: 2.25

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: $2.65 per share
• Price / Cash Flow: 1.51
• Book Value: $1.38 per share
• Price / Book: 2.90

Miscellaneous

• Outstanding Shares: 1,037,000
• Free Float: N/A
• Market Cap: $4.15 million
• Optionable: Not Optionable
• Beta: -0.08